Share Email Print

Proceedings Paper

Future of laser biostimulation in America today: microlight 830
Author(s): Chadwick F. Smith; C. Thomas Vangsness
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

For the last two years we have been investigating the use of a 830 nanometer laser for low level laser therapy in chronic pain syndromes. This laser is of low energy and by definition is low level therapy (a laser output which does not exceed 100 milliwatts). This wave length has been carefully selected to be in the 'window' of wavelengths between 650 and 900 nanometers. At this level, the laser energy will penetrate the epidermis, the dermis and the subcutaneous layers to the deep tissue. The tissue effect of this laser energy is not thermal but rather a stimulation of micro-circulation with a secondary effect of blocking pain enzymes and activation of the synthesis of endorphin enzymes. We have experience with approximately 75 patients who have been treated with low level laser therapy. We have engaged in a double- blind study at several General Motors facilities in Michigan to determine the effectiveness of low level laser therapy in this inflammatory condition. Repetitive injuries in the work place have moved from 18% of industrial accidents in 1981 to 52% in 1989. Carpal Tunnel Syndrome is the number one economic problem in occupational medicine. It is true that 15% of the employees of American automotive plants have Carpal Tunnel Syndrome. This large number of patients have been treated in the past by standard physiotherapy treatment modalities and ultimately by surgery for failure of conservative therapy. Incidence of 'return to work activities' has been low. We intend to show that low level laser therapy may afford a positive solution to this problem not only therapeutically but prophylactically. Indications for treatment are Chronic Pain Syndrome and Carpal Tunnel Syndrome of mild to moderate degree.

Paper Details

Date Published: 1 June 1992
PDF: 2 pages
Proc. SPIE 1643, Laser Surgery: Advanced Characterization, Therapeutics, and Systems III, (1 June 1992); doi: 10.1117/12.137353
Show Author Affiliations
Chadwick F. Smith, Univ. of Southern California School of Medicine (United States)
C. Thomas Vangsness, Univ. of Southern California School of Medicine (United States)

Published in SPIE Proceedings Vol. 1643:
Laser Surgery: Advanced Characterization, Therapeutics, and Systems III
R. Rox Anderson, Editor(s)

© SPIE. Terms of Use
Back to Top